Stockreport

Nuvation Bio Reports Third Quarter 2024 Financial Results and Provides Business Update

Nuvation Bio Inc. Class A  (NUVB) 
PDF Submitted New Drug Application (NDA) for taletrectinib to the U.S. Food and Drug Administration (FDA) in October for the treatment of patients with advanced ROS1-positiv [Read more]